$NAGE News
Last published 2d ago
- 2d agoNAGENiagen Bioscience Announces Participation in Upcoming Investor ConferencesBusiness WireLOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate in the following upcoming conferences: A.G.P. Virtual Consumer Showcase Virtual showcase offering consumer company management teams a platform t ...
- 1w agoNAGENiagen Bioscience, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 2w agoNAGENiagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth ExpansionBusiness WireLiquid formulation of Niagen™ Plus simplifies at-home administration and is the only at-home injection with clinical outcomes associated with reduced fatigue and improved sleep and skin Niagen Bioscience, Inc.
- 3w agoNAGENiagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® ProductBusiness WireFollowing a customer-favorite limited release, Niagen NanoCloud™ debuts the Tru Niagen® Skincare category with a first-of-its-kind waterless, precision-dosed sachet technology that keeps Niagen’s benefits protected
- 3w agoNAGENiagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026Business WireNiagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Wednesday,
- 1mo agoNAGEAndrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)Business WireThis award recognizes Dr. Shao’s dedication to advancing NAD+ research and scientific excellence responsibly within the dietary supplement industry Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+
- 1mo agoNAGENiagen Bioscience to Present at LD Micro 20th Annual Main EventBusiness WireNiagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate in the 20th
- 1mo agoNAGENiagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®” a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly SlaterBusiness WireThe campaign pairs a new perspective on aging with the Company’s 25+ years of quality and scientific leadership, including over 45 peer-reviewed published clinical studies on its flagship precursor ingredient Niagen®
- 1mo agoNAGENiagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical TrialBusiness WireProposed multi-year, randomized, placebo-controlled prevention trial would evaluate Niagen (patented nicotinamide riboside, or NR) supplementation across major clinical outcomes and healthy aging-related measures in
- 1mo agoNAGENewly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy OutcomesBusiness WirePreclinical study results showcase that CD38, an NAD-consuming enzyme more active with age and inflammation, leads to NAD+ depletion in placental tissue, while restoring NAD+ with the precursor NR improved placental,
- 2mo agoNAGENiagen Bioscience to Present at Canaccord Genuity’s Well SummitBusiness WireNiagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and
- 2mo agoNAGENiagen Bioscience to Present at Longevity Investors ConferenceBusiness WireNiagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the
- 2mo agoNAGENiagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF SummitBusiness WireNiagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate in the Nasdaq
- 2mo agoNAGENiagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s ClubBusiness WireLeading NAD+ healthy aging supplement reaches new health-conscious consumers at nearly 300 GNC and Sam’s Club locations across 44 states combined Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+
- 3mo agoNAGENiagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor ConferenceBusiness WireNiagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will present at the Midwest
- 3mo agoNAGENiagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace PresenceBusiness WireNew e-commerce availability broadens consumer access to the leading healthy-aging NAD+ supplement in the United States Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine
- 3mo agoNAGENiagen Bioscience, Inc. Reports Second Quarter 2026 Financial ResultsBusiness WireLaunched pharmaceutical program targeting rare genetic diseases and aging related disorders in July Launched Niagen Plus telehealth platform Net sales of $29.8 million, including $24.2 million from Tru
- 3mo agoNAGEEVONiagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168Business WireCollaboration will support pharmacokinetic, pharmacodynamic, and bioanalytical studies for Niagen Bioscience’s lead investigational candidate for rare pediatric diseasesEvotec brings deep drug development expertise,
- 3mo agoNAGENiagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological AgingBusiness WireNew epigenetic findings show Niagen NR reduces muscle biological aging and supports healthy muscle function Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with
- 3mo agoNAGENiagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth ConferenceBusiness WireNiagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and
- 3mo agoNAGENiagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026Business WireNiagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Tuesday,
- 3mo agoNAGENiagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External ResearchBusiness WireScientific leader with deep expertise in NAD+ biology, aging research, and global research partnerships to lead the Company's expanding Niagen Research ProgramNiagen Bioscience, Inc. (NASDAQ:NAGE), the global
- 4mo agoNAGENiagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)Business WireRegulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc.
- 4mo agoNAGENiagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026Business WireVirtual Q&A session to discuss the recently launched pharma program, the Company’s leadership in NAD+ science, and provide updates on Niagen Bioscience's business Niagen Bioscience, Inc. (NASDAQ:NAGE), the
- 4mo agoNAGENiagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic DiseasesBusiness WireNB4168, a patented therapeutic candidate designed to have significantly increased bioavailability and a differentiated safety and pharmacokinetic profile compared to NRC, is the first investigational product to advance
- 5mo agoNAGENiagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor ConferenceBusiness WireNiagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will present at the East Coast
- 5mo agoNAGENiagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ ScienceBusiness WireThe program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology
- 6mo agoNAGENiagen Bioscience Announces Participation in Upcoming Investor ConferencesBusiness WireNiagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate in the
- 6mo agoNAGENiagen Bioscience, Inc. Reports First Quarter 2026 Financial ResultsBusiness WireNet sales increased to $31.5 million Gross margin improved to 63.5% Net income of $6.3 million, up $1.3 million from the prior year and adjusted EBITDA of $3.8 million Niagen Bioscience, Inc. (NASDAQ:NAGE) today
- 6mo agoNAGENiagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit OfferingBusiness WireNew telehealth platform introduces prescription-only Niagen At-Home Injection Kit, expanding access to pharmaceutical-grade NAD+ support for cellular and tissue health delivered directly to eligible patients'
- 6mo agoNAGENiagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™Business WirePartnership unlocks Olympia's established clinic network for Niagen Plus, expands pharmaceutical-grade Niagen supply chain, and brings liquid compounded vials to market Niagen Bioscience, Inc. (NASDAQ:NAGE), the
- 6mo agoNAGENiagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026Business WireNiagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Wednesday, May
- 7mo agoNAGENiagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®Business WireNR is the first among NR, NMN, and NAD+ to receive a pharmacopeial quality benchmark, reinforcing Niagen Bioscience's leadership in NAD+ science and ingredient quality Niagen Bioscience, Inc. (NASDAQ:NAGE), the global
- 7mo agoNAGEOSWNiagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High SeasBusiness WireNiagen IV launches across Medi-Spa clinics on high-end cruise ships, expanding Niagen Plus' footprint Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a
- 7mo agoNAGENiagen Bioscience Increases Share Repurchase Program to $20 MillionBusiness WireNiagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has authorized an
- 7mo agoNAGENiagen Bioscience to Present at the 38th Annual ROTH ConferenceBusiness WireNiagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the 38th
- 7mo agoNAGENiagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical StudiesBusiness WireBy supporting investigator-initiated research worldwide, the program has helped establish Niagen Bioscience as a foundational force in advancing NAD+ understanding across the industry Niagen Bioscience, Inc.
- 8mo agoNAGENiagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®Business WireLaunch expands Niagen® into the growing skincare category through a limited-release model designed to generate consumer insights and inform future innovation Niagen Bioscience, Inc. (NASDAQ:NAGE), the global
- 8mo agoNAGENiagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025Business WireNet sales increased 30% year-over-year to $129.4 million in 2025 Gross margin increased 250 bps year-over-year to 64.3% in 2025 Net income increased 103% year-over-year to $17.4 million in 2025 Adjusted EBITDA increased
- 8mo agoGERNNTLANAGEOCGNInvestors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B MilestonePR NewswireMarket News Updates News Commentary - The global anti-aging therapy market is gaining serious momentum as people live longer and actively look for...
- 8mo agoNAGENiagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash TransactionBusiness WireDivestiture streamlines operations and advances the Company's strategy to fully exit non-core activities Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a
- 8mo agoNAGENiagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®Business WirePatent strengthens Niagen Bioscience's intellectual property moat in fast-growing NAD+-boosting IV and injectable delivery formats, supporting commercial expansion and deterring infringers Niagen Bioscience, Inc.
- 9mo agoNAGENiagen Bioscience is the Premiere Sponsor of the Inaugural "NAD for Health: Opportunities & Challenges" Conference Hosted by the University of CopenhagenBusiness WireTaking place March 23-25, 2026, this three-day scientific forum will convene the world's foremost NAD experts in Copenhagen to advance evidence-based dialogue and accelerate clinical translation Niagen Bioscience,
- 9mo agoNAGENiagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026Business WireNiagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, March 4,
- 9mo agoCGCNAGEZVIAFunctional Wellness Stocks Explode as $179 Billion Beverage Market Ditches Sugar for ScienceGlobeNewswireVANCOUVER, British Columbia, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The global functional beverage market is on a moonshot toward $179.26 billion in 2026[1]. This massive rotation is
- 9mo agoLEXXNAGEPMWSTTHE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke PointGlobeNewswireVANCOUVER, British Columbia, Jan. 21, 2026 (GLOBE NEWSWIRE) -- USA News Group - News Commentary – The $6.16 trillion health market is hitting a wall as consumers dump generic stimulants for $57.1 billion in precision
- 10mo agoNAGENiagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen's University BelfastBusiness WireThis acquisition establishes Niagen Bioscience as the sole owner of the most comprehensive and defensible intellectual property portfolio in the NAD+ industry Niagen Bioscience, Inc. (NASDAQ:NAGE), the global
- 12mo agoNAGENiagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)Business WireThis science-backed blend of Niagen and clinically studied actives is designed to support healthy skin, hair, and nails Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine
- 12mo agoNAGENiagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVIDBusiness WireFindings show a significant increase in NAD+ levels and within-group benefits in fatigue, depression, and sleep quality Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine
- 1y agoNAGENiagen Bioscience Announces $10 Million Share Repurchase ProgramBusiness WireNiagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has approved a share